Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
< or =,15613930,AUC,"However, significant increases in AUC and Cmax, and a significant reduction in Tmax by adding AsA were observed in 25 patients with baseline AUC < or =2500 ng.hour/mL.",The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15613930/),[h·ng] / [ml],2500,8056,DB00190,Carbidopa
,2685650,time to peak levodopa concentration,"Compared to standard Sinemet 25/100, time to peak levodopa concentration (2.3 versus 1.1 hrs), onset of maximal clinical improvement (2.2 versus 1.1 hrs), and other indices were significantly delayed with Sinemet CR.",Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685650/),h,2.3,10955,DB00190,Carbidopa
,2685650,time to peak levodopa concentration,"Compared to standard Sinemet 25/100, time to peak levodopa concentration (2.3 versus 1.1 hrs), onset of maximal clinical improvement (2.2 versus 1.1 hrs), and other indices were significantly delayed with Sinemet CR.",Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685650/),h,1.1,10956,DB00190,Carbidopa
,2685650,onset of maximal clinical improvement,"Compared to standard Sinemet 25/100, time to peak levodopa concentration (2.3 versus 1.1 hrs), onset of maximal clinical improvement (2.2 versus 1.1 hrs), and other indices were significantly delayed with Sinemet CR.",Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685650/),h,2.2,10957,DB00190,Carbidopa
,2685650,onset of maximal clinical improvement,"Compared to standard Sinemet 25/100, time to peak levodopa concentration (2.3 versus 1.1 hrs), onset of maximal clinical improvement (2.2 versus 1.1 hrs), and other indices were significantly delayed with Sinemet CR.",Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685650/),h,1.1,10958,DB00190,Carbidopa
,25875940,bioavailability,Levodopa bioavailability was 99 % for LCIG relative to LC-oral.,Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25875940/),%,99,13683,DB00190,Carbidopa
,30977301,Tmax,"For both formulations, the median Tmax for levodopa was 1.0 and 3.0 hours for carbidopa.",Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,1.0,19348,DB00190,Carbidopa
,30977301,Tmax,"For both formulations, the median Tmax for levodopa was 1.0 and 3.0 hours for carbidopa.",Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,3.0,19349,DB00190,Carbidopa
,30977301,half-life,The levodopa half-life harmonic mean was 1.6 hour for both formulations.,Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,1.6,19350,DB00190,Carbidopa
,30977301,half-life,"The carbidopa half-life harmonic mean was 1.9 and 2.0 hour, respectively, for the LCIG-HV and LCIG-LV formulations.",Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,1.9,19351,DB00190,Carbidopa
,30977301,half-life,"The carbidopa half-life harmonic mean was 1.9 and 2.0 hour, respectively, for the LCIG-HV and LCIG-LV formulations.",Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,2.0,19352,DB00190,Carbidopa
,15496222,AUC(0-12 h),"Donepezil PK assessments of PD patients receiving levodopa/carbidopa were similar to the PK results from healthy controls who received donepezil HCl only (mean AUC(0-12 h)= 281.6 +/- 17.6 and 268.6 +/- 19.9 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],281.6,28359,DB00190,Carbidopa
,15496222,AUC(0-12 h),"Donepezil PK assessments of PD patients receiving levodopa/carbidopa were similar to the PK results from healthy controls who received donepezil HCl only (mean AUC(0-12 h)= 281.6 +/- 17.6 and 268.6 +/- 19.9 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],268.6,28360,DB00190,Carbidopa
,15496222,AUC(0-8 h),"Carbidopa PK were not significantly altered by the concomitant administration of multiple doses of donepezil HCl, compared with when PD patients received placebo (mean AUC(0-8 h)= 921.8 +/- 160 and 821.8 +/- 113 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],921.8,28361,DB00190,Carbidopa
,15496222,AUC(0-8 h),"Carbidopa PK were not significantly altered by the concomitant administration of multiple doses of donepezil HCl, compared with when PD patients received placebo (mean AUC(0-8 h)= 921.8 +/- 160 and 821.8 +/- 113 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],821.8,28362,DB00190,Carbidopa
,15496222,C(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[ng] / [ml],2652,28363,DB00190,Carbidopa
,15496222,C(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[ng] / [ml],2077,28364,DB00190,Carbidopa
,15496222,t(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),h,1.7,28365,DB00190,Carbidopa
,15496222,t(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),h,2.9,28366,DB00190,Carbidopa
,11307044,Peak plasma L-Dopa levels,Peak plasma L-Dopa levels and area under the curve did not differ significantly between the first-ever dose and after 1 month of continuous treatment (0.9 +/- 0.1 vs.,"The pharmacokinetic profile of the ""first ever"" oral dose of levodopa in de novo patients with Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307044/),,0.9,32478,DB00190,Carbidopa
,15965309,AUC,"The mean (+/-SD) plasma levodopa AUC was 39% (P = 0.0001) higher with entacapone (11,802 +/- 1454 ng/hour/mL) compared with placebo (8465 +/- 927 ng/hour/mL).",Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15965309/),[ng] / [h·ml],"11,802",34890,DB00190,Carbidopa
,15965309,AUC,"The mean (+/-SD) plasma levodopa AUC was 39% (P = 0.0001) higher with entacapone (11,802 +/- 1454 ng/hour/mL) compared with placebo (8465 +/- 927 ng/hour/mL).",Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15965309/),[ng] / [h·ml],8465,34891,DB00190,Carbidopa
>,22632782,T(max),"The gastric emptying study showed that T(max) ((13)C)>60 min was more common in patients with a plasma levodopa peak at 2 hours (14/18, 69%) than in those with a plasma levodopa peak at 1 hour (4/13, 22%) (p<0.05), total of 50.7 ± 16.4 min in all 31 patients.",Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632782/),min,60,35327,DB00190,Carbidopa
,22632782,T(max),"The gastric emptying study showed that T(max) ((13)C)>60 min was more common in patients with a plasma levodopa peak at 2 hours (14/18, 69%) than in those with a plasma levodopa peak at 1 hour (4/13, 22%) (p<0.05), total of 50.7 ± 16.4 min in all 31 patients.",Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632782/),min,50,35328,DB00190,Carbidopa
,6187038,biological half-life,"The biological half-life of 5-HTP ranged from 2.2 to 7.4 hours, and the plasma clearance ranged from 0.10 to 0.23 1/kg/hour.",Kinetics of l-5-hydroxytryptophan in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6187038/),h,2.2 to 7.4,35579,DB00190,Carbidopa
,6187038,plasma clearance,"The biological half-life of 5-HTP ranged from 2.2 to 7.4 hours, and the plasma clearance ranged from 0.10 to 0.23 1/kg/hour.",Kinetics of l-5-hydroxytryptophan in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6187038/),[1] / [h·kg],0.10 to 0.23,35580,DB00190,Carbidopa
,6187038,bioavailability,The bioavailability of 5-HTP after oral administration in combination with carbidopa was calculated as 48% +/- 15 (mean +/- SD).,Kinetics of l-5-hydroxytryptophan in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6187038/),%,48,35581,DB00190,Carbidopa
,16320098,V1,"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·kg],11.4,40352,DB00190,Carbidopa
,16320098,CL,"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·h·kg],30.9,40353,DB00190,Carbidopa
,16320098,V2,"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·kg],27.3,40354,DB00190,Carbidopa
,16320098,CL(ic),"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·h·kg],34.6,40355,DB00190,Carbidopa
,1811168,Tmax,"The mean Tmax value of levodopa in plasma and muscle was 0.16 h and 1.0 h, respectively.",In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811168/),h,0.16,44183,DB00190,Carbidopa
,1811168,Tmax,"The mean Tmax value of levodopa in plasma and muscle was 0.16 h and 1.0 h, respectively.",In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811168/),h,1.0,44184,DB00190,Carbidopa
,15548480,onset of effect,"Compared with standard LD/CD, the 30 g mucuna preparation led to a considerably faster onset of effect (34.6 v 68.5 min; p = 0.021), reflected in shorter latencies to peak L-dopa plasma concentrations.",Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548480/),min,34.6,53141,DB00190,Carbidopa
,15548480,onset of effect,"Compared with standard LD/CD, the 30 g mucuna preparation led to a considerably faster onset of effect (34.6 v 68.5 min; p = 0.021), reflected in shorter latencies to peak L-dopa plasma concentrations.",Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548480/),min,68.5,53142,DB00190,Carbidopa
,6146680,biological t1/2,The estimated biological t1/2 was 5 h and the plasma clearance 0.0053 (litre kg-1) min-1.,The pharmacokinetic profile of carbidopa in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146680/),h,5,53381,DB00190,Carbidopa
,6146680,plasma clearance,The estimated biological t1/2 was 5 h and the plasma clearance 0.0053 (litre kg-1) min-1.,The pharmacokinetic profile of carbidopa in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146680/),[l] / [kg·min],0.0053,53382,DB00190,Carbidopa
,6146680,absolute bioavailability (F),The oral absorption of carbidopa was almost complete and the absolute bioavailability (F) was 88%.,The pharmacokinetic profile of carbidopa in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146680/),%,88,53383,DB00190,Carbidopa
,32554330,Cmax,"The Cmax of levodopa was 9.0 ± 4.0 ng/mL, Tmax was 41.4 ± 40.2 min, and area under the blood concentration-time curve up to 4 h (AUC4hr) was 12.3 ± 3.7 ng/mL*4hr.","Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554330/),[ng] / [ml],9.0,58534,DB00190,Carbidopa
,32554330,Tmax,"The Cmax of levodopa was 9.0 ± 4.0 ng/mL, Tmax was 41.4 ± 40.2 min, and area under the blood concentration-time curve up to 4 h (AUC4hr) was 12.3 ± 3.7 ng/mL*4hr.","Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554330/),min,41.4,58535,DB00190,Carbidopa
,32554330,area under the blood concentration-time curve up to 4 h (AUC4hr),"The Cmax of levodopa was 9.0 ± 4.0 ng/mL, Tmax was 41.4 ± 40.2 min, and area under the blood concentration-time curve up to 4 h (AUC4hr) was 12.3 ± 3.7 ng/mL*4hr.","Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554330/),[ng] / [4hr·ml],12.3,58536,DB00190,Carbidopa
,23229334,C(avg),"Mean (SD) C(avg) (μg/mL) were 2.9 (0.84) for levodopa, 17.1 (4.99) for 3-OMD, and 0.22 (0.08) for carbidopa.","Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229334/),[μg] / [ml],2.9,59538,DB00190,Carbidopa
,23229334,C(avg),"Mean (SD) C(avg) (μg/mL) were 2.9 (0.84) for levodopa, 17.1 (4.99) for 3-OMD, and 0.22 (0.08) for carbidopa.","Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229334/),[μg] / [ml],17.1,59539,DB00190,Carbidopa
,23229334,C(avg),"Mean (SD) C(avg) (μg/mL) were 2.9 (0.84) for levodopa, 17.1 (4.99) for 3-OMD, and 0.22 (0.08) for carbidopa.","Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229334/),[μg] / [ml],0.22,59540,DB00190,Carbidopa
,34366380,steady-state exposure,Foslevodopa/foscarbidopa infusion provides stable LD and CD exposures compared to oral LD/CD dosing with the average steady-state exposure ranging from 747-4660 ng/mL for the different groups.,Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34366380/),[ng] / [ml],747-4660,60341,DB00190,Carbidopa
,21856105,m/z,"Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),,212,60621,DB00190,Carbidopa
,21856105,m/z,"Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),,166,60622,DB00190,Carbidopa
,21856105,m/z,"Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),,227,60623,DB00190,Carbidopa
,21856105,m/z,"Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),,181,60624,DB00190,Carbidopa
higher,21856105,recovery rates,"The method shown to be specific, precise, accurate and provided recovery rates higher than 85% for all analytes.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),%,85,60625,DB00190,Carbidopa
,33093598,apparent clearances (CL/F),"The final model was a one compartment model with a high fixed absorption rate constant, and a first order elimination, with estimated apparent clearances (CL/F), of 27.9 L/h/70 kg for LCIG versus 17.5 L/h/70 kg for LECIG, and apparent volume of distribution of 74.4 L/70 kg.",Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33093598/),[l] / [70·h·kg],27.9,64634,DB00190,Carbidopa
,33093598,apparent clearances (CL/F),"The final model was a one compartment model with a high fixed absorption rate constant, and a first order elimination, with estimated apparent clearances (CL/F), of 27.9 L/h/70 kg for LCIG versus 17.5 L/h/70 kg for LECIG, and apparent volume of distribution of 74.4 L/70 kg.",Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33093598/),[l] / [70·h·kg],17.5,64635,DB00190,Carbidopa
,33093598,apparent volume of distribution,"The final model was a one compartment model with a high fixed absorption rate constant, and a first order elimination, with estimated apparent clearances (CL/F), of 27.9 L/h/70 kg for LCIG versus 17.5 L/h/70 kg for LECIG, and apparent volume of distribution of 74.4 L/70 kg.",Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33093598/),[l] / [70·kg],74.4,64636,DB00190,Carbidopa
,8780091,time of onset in,"The time of onset in clinical benefit was significantly earlier with Std-L (47 minutes, range 15 to 75 minutes) as the first dose as compared with L-CR (58 minutes, range 30 to 105 minutes).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),min,47,64766,DB00190,Carbidopa
,8780091,time of onset in,"The time of onset in clinical benefit was significantly earlier with Std-L (47 minutes, range 15 to 75 minutes) as the first dose as compared with L-CR (58 minutes, range 30 to 105 minutes).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),min,58,64767,DB00190,Carbidopa
,8780091,Tmax,"Similarly, there was a significant difference in the peak plasma dopa levels (Cmax) and the time to reach peak plasma dopa levels (Tmax) with administration of Std-L (Tmax 36 minutes; Cmax 1,501 micrograms/ml) as compared with L-CR (Tmax 111 minutes, Cmax 1,260 micrograms/ml).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),min,36,64768,DB00190,Carbidopa
,8780091,Cmax,"Similarly, there was a significant difference in the peak plasma dopa levels (Cmax) and the time to reach peak plasma dopa levels (Tmax) with administration of Std-L (Tmax 36 minutes; Cmax 1,501 micrograms/ml) as compared with L-CR (Tmax 111 minutes, Cmax 1,260 micrograms/ml).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),[μg] / [ml],"1,501",64769,DB00190,Carbidopa
,8780091,Tmax,"Similarly, there was a significant difference in the peak plasma dopa levels (Cmax) and the time to reach peak plasma dopa levels (Tmax) with administration of Std-L (Tmax 36 minutes; Cmax 1,501 micrograms/ml) as compared with L-CR (Tmax 111 minutes, Cmax 1,260 micrograms/ml).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),min,111,64770,DB00190,Carbidopa
,8780091,Cmax,"Similarly, there was a significant difference in the peak plasma dopa levels (Cmax) and the time to reach peak plasma dopa levels (Tmax) with administration of Std-L (Tmax 36 minutes; Cmax 1,501 micrograms/ml) as compared with L-CR (Tmax 111 minutes, Cmax 1,260 micrograms/ml).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),[μg] / [ml],"1,260",64771,DB00190,Carbidopa
,24339234,total daily off time,The mean total daily off time was reduced from baseline by a mean (± standard error) of 2.7 hours (± 0.48 hours) for immediate-release carbidopa-levodopa and 3.0 hours (± 0.57 hours) for XP21279-carbidopa (P = 0.49).,Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24339234/),h,2.7,66635,DB00190,Carbidopa
,24339234,total daily off time,The mean total daily off time was reduced from baseline by a mean (± standard error) of 2.7 hours (± 0.48 hours) for immediate-release carbidopa-levodopa and 3.0 hours (± 0.57 hours) for XP21279-carbidopa (P = 0.49).,Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24339234/),h,3.0,66636,DB00190,Carbidopa
,8133901,t 1/2 beta,The elimination half-life of L-dopa in the controls was higher in muscle (t 1/2 beta = 1.76 h) than in blood plasma (t 1/2 beta = 0.50 h).,The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8133901/),h,1.76,67810,DB00190,Carbidopa
,8133901,t 1/2 beta,The elimination half-life of L-dopa in the controls was higher in muscle (t 1/2 beta = 1.76 h) than in blood plasma (t 1/2 beta = 0.50 h).,The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8133901/),h,0.50,67811,DB00190,Carbidopa
,9695725,C50,"The second was C50(carbidopa) = 951 ng/ml; C50(benserazide) = 1238 ng/ml, where C50 is the steady-state plasma concentration of levodopa eliciting half of maximum attainable effect, and carbidopa and benserazide are the dopa decarboxylase inhibitors given in the study.",Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695725/),[ng] / [ml],951,69384,DB00190,Carbidopa
,9695725,C50,"The second was C50(carbidopa) = 951 ng/ml; C50(benserazide) = 1238 ng/ml, where C50 is the steady-state plasma concentration of levodopa eliciting half of maximum attainable effect, and carbidopa and benserazide are the dopa decarboxylase inhibitors given in the study.",Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695725/),[ng] / [ml],1238,69385,DB00190,Carbidopa
,18778758,gastric residence time,"It was shown that the three formulations offered almost the same mean gastric residence time, which was about 240 min.",Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18778758/),min,240,70100,DB00190,Carbidopa
,22377973,first maximum time,"Compared with C-ER, both gastroretentive ER tablets significantly extended the first maximum time (6.0 vs 2.5 h; P < 0.025) and had smoother plasma concentration-time profiles while achieving a similar maximum plasma concentration and area under the curve.",Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22377973/),h,6.0,71779,DB00190,Carbidopa
,22377973,first maximum time,"Compared with C-ER, both gastroretentive ER tablets significantly extended the first maximum time (6.0 vs 2.5 h; P < 0.025) and had smoother plasma concentration-time profiles while achieving a similar maximum plasma concentration and area under the curve.",Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22377973/),h,2.5,71780,DB00190,Carbidopa
,22377973,peak/trough ratio,PK modeling predicts a steady-state levodopa peak/trough ratio of 4 for both IR/ER and ER formulations and a ratio of 21 for C-ER.,Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22377973/),,4,71781,DB00190,Carbidopa
,28101657,time to maximum improvement,"The mean time to maximum improvement in sum of six UPDRS items score was 78 min (±59) (n = 16), and the mean time to TRS score maximum effect was 54 min (±51) (n = 15).",Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28101657/),min,78,78650,DB00190,Carbidopa
,28101657,time to TRS score maximum effect,"The mean time to maximum improvement in sum of six UPDRS items score was 78 min (±59) (n = 16), and the mean time to TRS score maximum effect was 54 min (±51) (n = 15).",Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28101657/),min,54,78651,DB00190,Carbidopa
,28101657,time to onset of dyskinesia,Mean time to onset of dyskinesia was 41 min (±38) (n = 13).,Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28101657/),min,41,78652,DB00190,Carbidopa
,12942590,Tmax,Tmax (time at which the maximal L-DOPA concentration was reached) were 69 +/- 12 min and 64 +/- 11 min for Sinemet and Grifoparkin respectively (NS).,[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),min,69,79425,DB00190,Carbidopa
,12942590,Tmax,Tmax (time at which the maximal L-DOPA concentration was reached) were 69 +/- 12 min and 64 +/- 11 min for Sinemet and Grifoparkin respectively (NS).,[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),min,64,79426,DB00190,Carbidopa
,12942590,Cmax (maximal L-DOPA concentration reached,Cmax (maximal L-DOPA concentration reached) was 3161 +/- 345 ng/ml for Sinemet and 3274 +/- 520 ng/ml for Grifoparkin (NS).,[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[ng] / [ml],3161,79427,DB00190,Carbidopa
,12942590,Cmax (maximal L-DOPA concentration reached,Cmax (maximal L-DOPA concentration reached) was 3161 +/- 345 ng/ml for Sinemet and 3274 +/- 520 ng/ml for Grifoparkin (NS).,[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[ng] / [ml],3274,79428,DB00190,Carbidopa
,12942590,t1/2 (half life time),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),min,159,79429,DB00190,Carbidopa
,12942590,CL (clearance),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[1] / [h],51.7,79430,DB00190,Carbidopa
,12942590,CL (clearance),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),min,161,79431,DB00190,Carbidopa
,12942590,CL (clearance),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[l] / [h],58.7,79432,DB00190,Carbidopa
,12942590,volume of distribution (Vd),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[l] / [kg],3.6,79433,DB00190,Carbidopa
,12942590,volume of distribution (Vd),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[l] / [kg],3.0,79434,DB00190,Carbidopa
,10606836,overall clearance,"The overall clearance of tolcapone could be estimated with good precision (approximately 4. 5-5 l h-1 ), and none of the investigated covariates (e.g. sex, age, body weight) had any clinically significant influence on this parameter.",Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606836/),[l] / [h],4. 5-5,80316,DB00190,Carbidopa
,10606836,volume of distribution,"The volume of distribution showed relatively high variability and was calculated to be approximately 30 l, leading to an estimated half-life in patients of approximately 5-8 h.",Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606836/),l,30,80317,DB00190,Carbidopa
,10606836,half-life,"The volume of distribution showed relatively high variability and was calculated to be approximately 30 l, leading to an estimated half-life in patients of approximately 5-8 h.",Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606836/),h,5-8,80318,DB00190,Carbidopa
,14646613,tmax,Plasma levodopa tmax was significantly shorter with all three modes of administration of etilevodopa (mean of about 30 minutes) than with levodopa treatment (mean of 54 minutes).,"Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646613/),min,30,93618,DB00190,Carbidopa
,14646613,tmax,Plasma levodopa tmax was significantly shorter with all three modes of administration of etilevodopa (mean of about 30 minutes) than with levodopa treatment (mean of 54 minutes).,"Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646613/),min,54,93619,DB00190,Carbidopa
,14646613,Cmax,Mean levodopa Cmax was in the range 2.3 to 2.7 microg/mL for all treatments.,"Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646613/),[μg] / [ml],2.3 to 2.7,93620,DB00190,Carbidopa
,25795100,Absolute bioavailability,Absolute bioavailability after 24 h transdermal delivery is 37 % of the applied rotigotine dose.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),%,37,99596,DB00190,Carbidopa
>,25795100,apparent volume of distribution,The drug shows a high apparent volume of distribution (>2500 L) and a total body clearance of 300-600 L/h.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),l,2500,99597,DB00190,Carbidopa
,25795100,total body clearance,The drug shows a high apparent volume of distribution (>2500 L) and a total body clearance of 300-600 L/h.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),[l] / [h],300-600,99598,DB00190,Carbidopa
,24433449,absorption,"The final model was a two compartment model with a transit compartment for absorption, first order elimination, bioavailability for LCIG (97%; confidence interval = 95% to 98%) relative to LC-oral, different first order transit absorption rate constants (LCIG = 9.2 h(-1) vs.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),%,97,101991,DB00190,Carbidopa
,24433449,"first order elimination, bioavailability","The final model was a two compartment model with a transit compartment for absorption, first order elimination, bioavailability for LCIG (97%; confidence interval = 95% to 98%) relative to LC-oral, different first order transit absorption rate constants (LCIG = 9.2 h(-1) vs.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),%,97,101992,DB00190,Carbidopa
,24433449,first order transit absorption rate constants,"The final model was a two compartment model with a transit compartment for absorption, first order elimination, bioavailability for LCIG (97%; confidence interval = 95% to 98%) relative to LC-oral, different first order transit absorption rate constants (LCIG = 9.2 h(-1) vs.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),1/[h],9.2,101993,DB00190,Carbidopa
,24433449,mean absorption time,"LC-oral = 2.4 h(-1) ; corresponding mean absorption time of 7 min for LCIG vs. 25 min for LC-oral) and different residual (intra-subject) variability for LCIG (15% proportional error, 0.3 μg ml(-1) additive error) vs. LC-oral (29% proportional error, 0.59 μg ml(-1) additive error).",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),min,7,101994,DB00190,Carbidopa
,24433449,mean absorption time,"LC-oral = 2.4 h(-1) ; corresponding mean absorption time of 7 min for LCIG vs. 25 min for LC-oral) and different residual (intra-subject) variability for LCIG (15% proportional error, 0.3 μg ml(-1) additive error) vs. LC-oral (29% proportional error, 0.59 μg ml(-1) additive error).",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),min,25,101995,DB00190,Carbidopa
,24433449,oral clearance,"Estimated oral clearance and steady-state volume of distribution for levodopa were 24.8 l h(-1) and 131 l, respectively.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),[l] / [h],24.8,101996,DB00190,Carbidopa
,24433449,steady-state volume of distribution,"Estimated oral clearance and steady-state volume of distribution for levodopa were 24.8 l h(-1) and 131 l, respectively.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),l,131,101997,DB00190,Carbidopa
,18850046,C(max),"After 7 days of treatment, the levodopa AUC increased by 12.6% from day 1 (range: 114.2-150.7 microg.min/ml) to day 7 (range: 131.1-166.0 microg.min/ml) and C(max) increased by 9.6% (range: 1.90-2.86 microg/ml on day 1 and 2.12-3.13 microg/ml on day 7).",Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18850046/),[μg] / [ml],1.90-2.86,105132,DB00190,Carbidopa
,18850046,C(max),"After 7 days of treatment, the levodopa AUC increased by 12.6% from day 1 (range: 114.2-150.7 microg.min/ml) to day 7 (range: 131.1-166.0 microg.min/ml) and C(max) increased by 9.6% (range: 1.90-2.86 microg/ml on day 1 and 2.12-3.13 microg/ml on day 7).",Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18850046/),[μg] / [ml],2.12-3.13,105133,DB00190,Carbidopa
,18850046,C(max),"After 14 days of treatment, the increase in AUC was 17.0% (range: 119.6-160.1 microg.min/ml on day 1 and 142.9-172.7 microg.min/ml on day 14) and C(max) increased by 6.5% (range: 2.29-2.96 microg/ml on day 1 and 2.41-3.07 microg/ml on day 14).",Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18850046/),[μg] / [ml],2.29-2.96,105134,DB00190,Carbidopa
,18850046,C(max),"After 14 days of treatment, the increase in AUC was 17.0% (range: 119.6-160.1 microg.min/ml on day 1 and 142.9-172.7 microg.min/ml on day 14) and C(max) increased by 6.5% (range: 2.29-2.96 microg/ml on day 1 and 2.41-3.07 microg/ml on day 14).",Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18850046/),[μg] / [ml],2.41-3.07,105135,DB00190,Carbidopa
,25855267,Bioavailability,"Bioavailability of LD from ER CD-LD was 83.5%, 78.3%, and 58.8% relative to IR CD-LD, CR CD-LD, and CD-LD-entacapone, respectively.","Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25855267/),%,83.5,105136,DB00190,Carbidopa
,25855267,Bioavailability,"Bioavailability of LD from ER CD-LD was 83.5%, 78.3%, and 58.8% relative to IR CD-LD, CR CD-LD, and CD-LD-entacapone, respectively.","Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25855267/),%,78.3,105137,DB00190,Carbidopa
,25855267,Bioavailability,"Bioavailability of LD from ER CD-LD was 83.5%, 78.3%, and 58.8% relative to IR CD-LD, CR CD-LD, and CD-LD-entacapone, respectively.","Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25855267/),%,58.8,105138,DB00190,Carbidopa
,22762460,FI,"FI for dose 2-5 was on average 1.26 for levodopa in LC-5, and 2.23 for dose 1-2 of LCE.",Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762460/),,1.26,105533,DB00190,Carbidopa
,22762460,FI,"FI for dose 2-5 was on average 1.26 for levodopa in LC-5, and 2.23 for dose 1-2 of LCE.",Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762460/),,2.23,105534,DB00190,Carbidopa
,31595429,bioavailability,Both the ODE and the SDE models estimated bioavailability to be approximately 75%.,Investigating Stochastic Differential Equations Modelling for Levodopa Infusion in Patients with Parkinson's Disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31595429/),%,75,111266,DB00190,Carbidopa
,21297456,mean absorption time,"Estimated population parameter values were a mean absorption time of 28.5 minutes, a lag time of 2.9 minutes, and a bioavailability of 88%.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),min,28.5,112475,DB00190,Carbidopa
,21297456,lag time,"Estimated population parameter values were a mean absorption time of 28.5 minutes, a lag time of 2.9 minutes, and a bioavailability of 88%.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),min,2.9,112476,DB00190,Carbidopa
,21297456,bioavailability,"Estimated population parameter values were a mean absorption time of 28.5 minutes, a lag time of 2.9 minutes, and a bioavailability of 88%.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),%,88,112477,DB00190,Carbidopa
,21297456,half-life of effect delay,"The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an Emax of 2.39 U on the treatment response scale, and a sigmoidicity of the Emax function of 11.6.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),min,21,112478,DB00190,Carbidopa
,21297456,concentration at 50% effect,"The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an Emax of 2.39 U on the treatment response scale, and a sigmoidicity of the Emax function of 11.6.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),[mg] / [l],1.55,112479,DB00190,Carbidopa
,21297456,Emax,"The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an Emax of 2.39 U on the treatment response scale, and a sigmoidicity of the Emax function of 11.6.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),u,2.39,112480,DB00190,Carbidopa
,21297456,Emax,"The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an Emax of 2.39 U on the treatment response scale, and a sigmoidicity of the Emax function of 11.6.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),,11,112481,DB00190,Carbidopa
,8813223,time to peak plasma concentrations,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),min,49,117571,DB00190,Carbidopa
,8813223,time to peak plasma concentrations,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),min,47,117572,DB00190,Carbidopa
,8813223,peak plasma concentration,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),[ng] / [ml],"1,273",117573,DB00190,Carbidopa
,8813223,peak plasma concentration,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),[ng] / [ml],"1,153",117574,DB00190,Carbidopa
,8813223,area under the curve,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),[μg] / [h·ml],"2,295",117575,DB00190,Carbidopa
,8813223,area under the curve,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),[μg] / [h·ml],"2,330",117576,DB00190,Carbidopa
,26861609,t1/2,"Pharmacokinetic studies showed elimination half-life of l-DOPA in the plasma after DopAmide treatment of t1/2 = 4.1 h, significantly longer than t1/2 = 2.9 h after treatment with l-DOPA, consistent with the 6-OHDA results.","DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861609/),h,4.1,117581,DB00190,Carbidopa
,26861609,t1/2,"Pharmacokinetic studies showed elimination half-life of l-DOPA in the plasma after DopAmide treatment of t1/2 = 4.1 h, significantly longer than t1/2 = 2.9 h after treatment with l-DOPA, consistent with the 6-OHDA results.","DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861609/),h,2.9,117582,DB00190,Carbidopa
,10510160,"AUC(0,tau)","The mean AUC(0,tau) and Cmax values at baseline were 0.39 microg ml-1 h and 0. 14 microg ml-1, respectively.",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[h·μg] / [ml],0.39,121517,DB00190,Carbidopa
,10510160,Cmax,"The mean AUC(0,tau) and Cmax values at baseline were 0.39 microg ml-1 h and 0. 14 microg ml-1, respectively.",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[μg] / [ml],0. 14,121518,DB00190,Carbidopa
,10510160,"AUC(0,tau)","During tolcapone treatment these values were on average 0.35 microg ml-1 h (AUC(0,tau), week 1-2), 0. 34 microg ml-1 h (AUC(0,tau), week 6 and 0.13 microg ml-1 (Cmax, weeks 1-2 and 6).",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[h·μg] / [ml],0.35,121519,DB00190,Carbidopa
,10510160,"AUC(0,tau)","During tolcapone treatment these values were on average 0.35 microg ml-1 h (AUC(0,tau), week 1-2), 0. 34 microg ml-1 h (AUC(0,tau), week 6 and 0.13 microg ml-1 (Cmax, weeks 1-2 and 6).",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[h·μg] / [ml],0. 34,121520,DB00190,Carbidopa
,10510160,Cmax,"During tolcapone treatment these values were on average 0.35 microg ml-1 h (AUC(0,tau), week 1-2), 0. 34 microg ml-1 h (AUC(0,tau), week 6 and 0.13 microg ml-1 (Cmax, weeks 1-2 and 6).",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[μg] / [ml],0.13,121521,DB00190,Carbidopa
,10510160,tmax,tmax remained unchanged (approx. 2 h).,COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),h,2,121522,DB00190,Carbidopa
,311987,apparent composite 1. order rate constants alpha,"The apparent composite 1. order rate constants alpha and beta were 1.433 hr-1 +/- 0.177 S.D. and 0.113 hr-1 +/- 0.012 hr-1 S.D., respectively.",Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311987/),1/[h],1.433,133074,DB00190,Carbidopa
,311987,beta,"The apparent composite 1. order rate constants alpha and beta were 1.433 hr-1 +/- 0.177 S.D. and 0.113 hr-1 +/- 0.012 hr-1 S.D., respectively.",Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311987/),1/[h],0.113,133075,DB00190,Carbidopa
,311987,biological half-life,The biological half-life of 5-hydroxytryptophan under the experimental conditions was thus about 6 hours.,Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311987/),h,6,133076,DB00190,Carbidopa
,311987,"apparent volume of the central compartment, Vc","The apparent volume of the central compartment, Vc, was found to be 0.336 1 kg-1 +/- 0.059 S.D. and the plasma clearance 0.105 1 hr-1 kg-1 +/- 0.015 S.D.",Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311987/),[1] / [kg],0.336,133077,DB00190,Carbidopa
,311987,plasma clearance,"The apparent volume of the central compartment, Vc, was found to be 0.336 1 kg-1 +/- 0.059 S.D. and the plasma clearance 0.105 1 hr-1 kg-1 +/- 0.015 S.D.",Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311987/),[1] / [h·kg],0.105,133078,DB00190,Carbidopa
,7931323,k0D,"After intravenous injection, FDOPA in circulation was O-methylated (k0D = 0.055 min-1), and the metabolite (O-methyl-FDOPA) escaped from plasma with a rate constant (k-1M) of 0.01 min-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),1/[min],0.055,134094,DB00190,Carbidopa
,7931323,rate constant (k-1M),"After intravenous injection, FDOPA in circulation was O-methylated (k0D = 0.055 min-1), and the metabolite (O-methyl-FDOPA) escaped from plasma with a rate constant (k-1M) of 0.01 min-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),1/[min],0.01,134095,DB00190,Carbidopa
,7931323,initial clearance of FDOPA to striatum (K1D),"The initial clearance of FDOPA to striatum (K1D) was 0.07 ml g-1 min-1, and the equilibrium distribution volume (VeD) was 0.67 ml g-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),[ml] / [g·min],0.07,134096,DB00190,Carbidopa
,7931323,equilibrium distribution volume (VeD),"The initial clearance of FDOPA to striatum (K1D) was 0.07 ml g-1 min-1, and the equilibrium distribution volume (VeD) was 0.67 ml g-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),[ml] / [g],0.67,134097,DB00190,Carbidopa
,7931323,initial clearance,"The initial clearance of O-methyl-FDOPA to striatum (K1M) was 0.08 ml g-1 min-1, and the equilibrium distribution volume (VeM) was 0.75 ml g-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),[ml] / [g·min],0.08,134098,DB00190,Carbidopa
,7931323,equilibrium distribution volume (VeM),"The initial clearance of O-methyl-FDOPA to striatum (K1M) was 0.08 ml g-1 min-1, and the equilibrium distribution volume (VeM) was 0.75 ml g-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),[ml] / [g],0.75,134099,DB00190,Carbidopa
,7931323,rate constant of FDOP,The rate constant of FDOPA decarboxylation (k3D) was 0.17 min-1 in striatum.,A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),1/[min],0.17,134100,DB00190,Carbidopa
,7931323,apparent rate constant,"The elimination of 6-[18F]fluorodopamine (FDA) from striatum suggested an apparent rate constant for monoamine oxidase activity (k7') of 0.055 min-1. 6-[18F]Fluorohomovanillic acid (FHVA) was formed from 6-[18F]fluoro-L-3,4-dihydroxyphenylacetic acid with a rate constant (k11) of 0.083 min-1, and FHVA was eliminated from striatum (k9) with a rate constant of 0.12 min-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),1/[min],0.055,134101,DB00190,Carbidopa
,7931323,rate constant (k11),"The elimination of 6-[18F]fluorodopamine (FDA) from striatum suggested an apparent rate constant for monoamine oxidase activity (k7') of 0.055 min-1. 6-[18F]Fluorohomovanillic acid (FHVA) was formed from 6-[18F]fluoro-L-3,4-dihydroxyphenylacetic acid with a rate constant (k11) of 0.083 min-1, and FHVA was eliminated from striatum (k9) with a rate constant of 0.12 min-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),1/[min],0.083,134102,DB00190,Carbidopa
,7931323,rate constant,"The elimination of 6-[18F]fluorodopamine (FDA) from striatum suggested an apparent rate constant for monoamine oxidase activity (k7') of 0.055 min-1. 6-[18F]Fluorohomovanillic acid (FHVA) was formed from 6-[18F]fluoro-L-3,4-dihydroxyphenylacetic acid with a rate constant (k11) of 0.083 min-1, and FHVA was eliminated from striatum (k9) with a rate constant of 0.12 min-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),1/[min],0.12,134103,DB00190,Carbidopa
,26366963,peak plasma LD concentration (Cmax),"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l],2.0,135959,DB00190,Carbidopa
,26366963,peak plasma LD concentration (Cmax),"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l],1.0,135960,DB00190,Carbidopa
,26366963,area under the plasma concentration time curve,"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l·min],137,135961,DB00190,Carbidopa
,26366963,area under the plasma concentration time curve,"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l·min],33.6,135962,DB00190,Carbidopa
,26366963,Cmax,"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l],0.7,135963,DB00190,Carbidopa
,12865145,steady-state levodopa concentrations,"At higher doses (target steady-state levodopa concentrations of 2,169 and 1,200 ng/ml), treatment-naive volunteers had unacceptably frequent side effects.",Rapid intravenous loading of levodopa for human research: clinical results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865145/),[ng] / [ml],"2,169",136647,DB00190,Carbidopa
,12865145,steady-state levodopa concentrations,"At higher doses (target steady-state levodopa concentrations of 2,169 and 1,200 ng/ml), treatment-naive volunteers had unacceptably frequent side effects.",Rapid intravenous loading of levodopa for human research: clinical results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865145/),[ng] / [ml],"1,200",136648,DB00190,Carbidopa
,12865145,steady-state concentration,"The final infusion protocol, with a target steady-state concentration of 600 ng/ml, was well-tolerated (mild nausea in 11% of subjects was the only side effect occurring significantly more than in single-blind saline infusions), produced the desired plasma levodopa concentration (612+/-187 ng/ml, mean+/-S.D.), and produced statistically significant antiparkinsonian benefit (16% mean reduction in a standard rating of parkinsonian motor signs, P<0.0005).",Rapid intravenous loading of levodopa for human research: clinical results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865145/),[ng] / [ml],600,136649,DB00190,Carbidopa
,10552081,half-life,The fast component of the decay accounted for 40%-50% of the radioactivity and had a half-life of about 5 min.,The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552081/),min,5,138434,DB00190,Carbidopa
,10552081,half-life,The slow component of the decay had a half-life of about 6 h in the subjects not taking carbidopa and 20 h in the patients taking carbidopa.,The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552081/),h,6,138435,DB00190,Carbidopa
,10552081,half-life,The slow component of the decay had a half-life of about 6 h in the subjects not taking carbidopa and 20 h in the patients taking carbidopa.,The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552081/),h,20,138436,DB00190,Carbidopa
,8730980,total AUC,Benzhexol administration did not affect the total AUC of levodopa (7.30 +/- 1.09 vs 7.19 +/- 1.26 micrograms ml-1 h; means +/- s.d.).,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],7.30,140754,DB00190,Carbidopa
,8730980,total AUC,Benzhexol administration did not affect the total AUC of levodopa (7.30 +/- 1.09 vs 7.19 +/- 1.26 micrograms ml-1 h; means +/- s.d.).,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],7.19,140755,DB00190,Carbidopa
,8730980,total AUC,The total AUC of paracetamol was not affected by benzhexol administration (39.4 +/- 8.2 vs 40.0 +/- 8.9 micrograms ml-1 h; mean +/- s.d.) 4.,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],39.4,140756,DB00190,Carbidopa
,8730980,total AUC,The total AUC of paracetamol was not affected by benzhexol administration (39.4 +/- 8.2 vs 40.0 +/- 8.9 micrograms ml-1 h; mean +/- s.d.) 4.,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],40.0,140757,DB00190,Carbidopa
,7739350,concentrations,"When carbidopa was given intraperitoneally at a dose of 2.5 and 5 mg/kg and intravenously at 5 mg/kg, plasma carbidopa concentrations at the time of Fdopa injection were 0.95 +/- 0.26, 2.22 +/- 0.23 and 2.79 +/- 0.26 micrograms/ml, respectively.",Routes of administration and effect of carbidopa pretreatment on 6-[18F]fluoro-L-dopa/PET scans in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7739350/),,2.22,143672,DB00190,Carbidopa
,7739350,concentrations,"When carbidopa was given intraperitoneally at a dose of 2.5 and 5 mg/kg and intravenously at 5 mg/kg, plasma carbidopa concentrations at the time of Fdopa injection were 0.95 +/- 0.26, 2.22 +/- 0.23 and 2.79 +/- 0.26 micrograms/ml, respectively.",Routes of administration and effect of carbidopa pretreatment on 6-[18F]fluoro-L-dopa/PET scans in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7739350/),,2.79,143673,DB00190,Carbidopa
,3427559,Time to peak plasma levodopa concentration,"Time to peak plasma levodopa concentration increased threefold (from 45 +/- 23 to 134 +/- 76 min, p less than 0.001), when levodopa was administered after meals.",Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427559/),min,45,146617,DB00190,Carbidopa
,3427559,Time to peak plasma levodopa concentration,"Time to peak plasma levodopa concentration increased threefold (from 45 +/- 23 to 134 +/- 76 min, p less than 0.001), when levodopa was administered after meals.",Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427559/),min,134,146618,DB00190,Carbidopa
,25649051,Maximum COMT inhibition (Emax),Maximum COMT inhibition (Emax) ranged from 52% (5 mg OPC) to 80% (30 mg OPC).,"Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649051/),%,52,147219,DB00190,Carbidopa
,25649051,Maximum COMT inhibition (Emax),Maximum COMT inhibition (Emax) ranged from 52% (5 mg OPC) to 80% (30 mg OPC).,"Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649051/),%,80,147220,DB00190,Carbidopa
,19412946,area-under-the-concentration-curve,"PK analysis revealed the anticipated near-equivalent mean L-dopa area-under-the-concentration-curve values (639,490 ng min/mL for two doses of CLE, and 662,577 for CL-CR, P = 0.86).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),[min·ng] / [ml],"639,490",150783,DB00190,Carbidopa
,19412946,area-under-the-concentration-curve,"PK analysis revealed the anticipated near-equivalent mean L-dopa area-under-the-concentration-curve values (639,490 ng min/mL for two doses of CLE, and 662,577 for CL-CR, P = 0.86).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),,"662,577",150784,DB00190,Carbidopa
,19412946,maximal concentration,"The mean maximal concentration for the first CLE dose was 1,926 +/- 760 ng/mL and for CL-CR, 1,840 +/- 889 (P = 0.33).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),[ng] / [ml],"1,926",150785,DB00190,Carbidopa
,19412946,CL-CR,"The mean maximal concentration for the first CLE dose was 1,926 +/- 760 ng/mL and for CL-CR, 1,840 +/- 889 (P = 0.33).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),,"1,840",150786,DB00190,Carbidopa
,19412946,CL-CR,"During the PK studies, the mean time that L-dopa concentration was > or =1,000 ng/mL for CLE was 291 +/- 88 minutes and for CL-CR, 306 +/- 86 (P = 0.33).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),,306,150787,DB00190,Carbidopa
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,18,150788,DB00190,Carbidopa
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,28,150789,DB00190,Carbidopa
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,64,150790,DB00190,Carbidopa
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,65,150791,DB00190,Carbidopa
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,7,150792,DB00190,Carbidopa
,8223831,relative bioavailability,The relative bioavailability of levodopa in the solid preparation compared to the dispersion was in all patients 100%.,Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223831/),%,100,153859,DB00190,Carbidopa
,1327609,bio-availability,"Actual total daily levodopa dosage in patients treated with Sinemet CR was increased by 33%; however, the plasma level of this dosage is calculated to be similar to that of the previous dosage of Sinemet-STD (bio-availability of Sinemet CR is 71%).","Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1327609/),%,71,155796,DB00190,Carbidopa
,29959802,Cmax,"L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively.","Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959802/),,88.4,157833,DB00190,Carbidopa
,29959802,AUC0-t,"L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively.","Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959802/),,89.5,157834,DB00190,Carbidopa
,29959802,AUC0-inf,"L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively.","Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959802/),,89.6,157835,DB00190,Carbidopa
,33296447,zeta potential,The mean (SD) size of levodopa microparticles was 0.5 (0.05) µm with polydispersity index of 0.41 and a zeta potential of 10.8 mV.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),mv,10.8,158058,DB00190,Carbidopa
,33296447,drug loading capacity,"Of the expected 20% drug loading, the actual drug loading capacity of levodopa microparticles was found to be 19.1%, giving an encapsulation efficiency of 95.7%.",Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),%,19.1,158059,DB00190,Carbidopa
,33296447,AUC,In vivo pharmacokinetic studies showed that rats administered levodopa/carbidopa microparticles had greater AUC (612.7 [17.42] ng.h/mL) and higher Cmax (262.4 [38.86] ng/mL) compared with Sinemet CR: AUC 354.7 (98.09) ng.h/mL and Cmax 95.5 (20.87) ng/mL.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),[h·ng] / [ml],612.7,158060,DB00190,Carbidopa
,33296447,Cmax,In vivo pharmacokinetic studies showed that rats administered levodopa/carbidopa microparticles had greater AUC (612.7 [17.42] ng.h/mL) and higher Cmax (262.4 [38.86] ng/mL) compared with Sinemet CR: AUC 354.7 (98.09) ng.h/mL and Cmax 95.5 (20.87) ng/mL.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),[ng] / [ml],262.4,158061,DB00190,Carbidopa
,33296447,AUC,In vivo pharmacokinetic studies showed that rats administered levodopa/carbidopa microparticles had greater AUC (612.7 [17.42] ng.h/mL) and higher Cmax (262.4 [38.86] ng/mL) compared with Sinemet CR: AUC 354.7 (98.09) ng.h/mL and Cmax 95.5 (20.87) ng/mL.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),[h·ng] / [ml],354.7,158062,DB00190,Carbidopa
,33296447,Cmax,In vivo pharmacokinetic studies showed that rats administered levodopa/carbidopa microparticles had greater AUC (612.7 [17.42] ng.h/mL) and higher Cmax (262.4 [38.86] ng/mL) compared with Sinemet CR: AUC 354.7 (98.09) ng.h/mL and Cmax 95.5 (20.87) ng/mL.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),[ng] / [ml],95.5,158063,DB00190,Carbidopa
,33296447,half-life,"However, Sinemet CR had a much longer half-life (6.1 [2.58] hours) compared with levodopa/carbidopa microparticles (2.0 [0.31] hours).",Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),h,6.1,158064,DB00190,Carbidopa
,33296447,half-life,"However, Sinemet CR had a much longer half-life (6.1 [2.58] hours) compared with levodopa/carbidopa microparticles (2.0 [0.31] hours).",Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),h,2.0,158065,DB00190,Carbidopa
,18719048,Nausea,"Compared to placebo, VAS Nausea increased non-significantly with granisetron [+7.6 mm (-1.3; 16.5)], as opposed to domperidone [+16.2 mm (7.2; 25.2)] and 5-HTP/CBD/placebo [+14.7 mm (5.5; 23.8)].",Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719048/),,7,161535,DB00190,Carbidopa
,18719048,Nausea,"Compared to placebo, VAS Nausea increased non-significantly with granisetron [+7.6 mm (-1.3; 16.5)], as opposed to domperidone [+16.2 mm (7.2; 25.2)] and 5-HTP/CBD/placebo [+14.7 mm (5.5; 23.8)].",Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719048/),,14,161536,DB00190,Carbidopa
,18719048,C(max),"Compared with 5-HTP/CBD/placebo, granisetron addition decreased C(max) of 5-HTP statistically significantly different (from 1483 to 1272 ng/ml) without influencing AUC(0- infinity).",Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719048/),[ng] / [ml],1483,161537,DB00190,Carbidopa
,9316692,plasma half-life,"As predicted from the plasma half-life (1.7 +/- 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily.",Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316692/),h,1.7,163196,DB00190,Carbidopa
,17654694,C(max),"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[ng] / [ml],1001,165310,DB00190,Carbidopa
,17654694,C(max),"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[ng] / [ml],1082,165311,DB00190,Carbidopa
,17654694,C(max),"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[ng] / [ml],1549,165312,DB00190,Carbidopa
,17654694,C(max),"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[ng] / [ml],1663,165313,DB00190,Carbidopa
,17654694,AUC,"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[h·ng] / [ml],1661,165314,DB00190,Carbidopa
,17654694,AUC,"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[h·ng] / [ml],1665,165315,DB00190,Carbidopa
,17654694,AUC,"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[h·ng] / [ml],2462,165316,DB00190,Carbidopa
,17654694,AUC,"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[h·ng] / [ml],2482,165317,DB00190,Carbidopa
greater,2778650,oral LD50,It was also noted that the oral LD50 value of 1 was greater than 6 g/kg in mice.,A new potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778650/),[g] / [kg],6,167319,DB00190,Carbidopa
,15090932,Time to return to baseline,"Time to return to baseline COMT activity ranged from 6 (50 mg) to 18 hours (400 mg), following the same dose-dependent tendency.","Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090932/),h,6,170488,DB00190,Carbidopa
,15090932,Time to return to baseline,"Time to return to baseline COMT activity ranged from 6 (50 mg) to 18 hours (400 mg), following the same dose-dependent tendency.","Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090932/),h,18,170489,DB00190,Carbidopa
,3124856,Km,"Determination of the Michaelis-Menten kinetic constants for aromatic amino acid decarboxylase AADC, EC 4.1.1.26) indicated that the Km for L-2-18F-DOPA (982 +/- 115 microM) was considerably higher than that for L-6-18F-DOPA (101 +/- 22 microM).",Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3124856/),μM,982,176242,DB00190,Carbidopa
,3124856,Km,"Determination of the Michaelis-Menten kinetic constants for aromatic amino acid decarboxylase AADC, EC 4.1.1.26) indicated that the Km for L-2-18F-DOPA (982 +/- 115 microM) was considerably higher than that for L-6-18F-DOPA (101 +/- 22 microM).",Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3124856/),μM,101,176243,DB00190,Carbidopa
,7791104,elimination half-life,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,2.66,177336,DB00190,Carbidopa
,7791104,volume of distribution by area,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177337,DB00190,Carbidopa
,7791104,AUC,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177338,DB00190,Carbidopa
,7791104,t1/2,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177339,DB00190,Carbidopa
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],1.0,184129,DB00190,Carbidopa
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.4,184130,DB00190,Carbidopa
,8612386,area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],10.1,184131,DB00190,Carbidopa
,8612386,area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],18.3,184132,DB00190,Carbidopa
,8612386,AUC[0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],17.3,184133,DB00190,Carbidopa
,8612386,AUC[0 - infinity),"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[h·mg] / [l],18.3,184134,DB00190,Carbidopa
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.2,184135,DB00190,Carbidopa
,8612386,Cmax,"At variance with the iron gluconate formulation, which led to a reduction of about 50% of peak serum ciprofloxacin levels (Cmax; 1.0 +/- 0.2 versus 2.4 +/- 0.3 micrograms/ml; p < 0.01) and of the area under the serum concentration-time curve from time 0 to infinity [AUC(0 - infinity); 10.1 +/- 1.1 versus 18.3 +/- 1.0 mg.L-1.hr; p < 0.01], the iron-ovotransferrin complex caused only modest, non significant changes in absorption with a minimal reduction of the AUC[0 - infinity) (17.3 +/- 1.0 versus 18.3 +/- 1.0 mg.L-1.hr; difference not significant) and a nonsignificant decrease in the Cmax (2.2 +/- 0.3 versus 2.4 +/- 0.3 microgram/ml; difference not significant).",Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612386/),[μg] / [ml],2.4,184136,DB00190,Carbidopa
,3085927,peak plasma Dopa concentrations,"Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h.",Effect of supplemental carbidopa on bioavailability of L-dopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085927/),[ng] / [ml],"1,893",187197,DB00190,Carbidopa
,3085927,peak plasma Dopa concentrations,"Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h.",Effect of supplemental carbidopa on bioavailability of L-dopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085927/),[ng] / [ml],"2,733",187198,DB00190,Carbidopa
,3085927,time to peak plasma concentration,"Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h.",Effect of supplemental carbidopa on bioavailability of L-dopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085927/),h,0.7,187199,DB00190,Carbidopa
,3085927,time to peak plasma concentration,"Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h.",Effect of supplemental carbidopa on bioavailability of L-dopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085927/),h,1.2,187200,DB00190,Carbidopa
,10492060,t1/2,"The mean t1/2 values of entacapone were 1.3 h and 1.8 h during the first and sixth days, respectively; the difference was not significant.",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,1.3,190584,DB00190,Carbidopa
,10492060,t1/2,"The mean t1/2 values of entacapone were 1.3 h and 1.8 h during the first and sixth days, respectively; the difference was not significant.",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,1.8,190585,DB00190,Carbidopa
,10492060,Cmax,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,2.4,190586,DB00190,Carbidopa
,10492060,t1/2,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,2.4,190587,DB00190,Carbidopa
,10492060,t1/2,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,2.3,190588,DB00190,Carbidopa
,10492060,tmax,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,0.8,190589,DB00190,Carbidopa
,10492060,tmax,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,1.2,190590,DB00190,Carbidopa
,6966118,systemic availability,"The systemic availability of L-5-hydroxytryptophan exhibited an interindividual range of 47-84%, with a mean value of 69.2% +/- 4.7 S.E.M.",Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6966118/),%,47-84,192852,DB00190,Carbidopa
,6966118,systemic availability,"The systemic availability of L-5-hydroxytryptophan exhibited an interindividual range of 47-84%, with a mean value of 69.2% +/- 4.7 S.E.M.",Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6966118/),%,69.2,192853,DB00190,Carbidopa
,23548675,run time,"To our knowledge, this is the first UHPLC-MS/MS based method that utilizes derivatization with fluorescamine and provides adequate sensitivity for both levodopa and carbidopa with 50 μL of sample and a run time of 3.5 min.",Development and validation of a simple and sensitive method for quantification of levodopa and carbidopa in rat and monkey plasma using derivatization and UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23548675/),min,3.5,200291,DB00190,Carbidopa
,20220040,peak increase,"The peak increase in plasma NE (0.57 ± 0.11 nmol/L) averaged less than 1/15,000 th that in L-DOPS and less than 1/35th that in DHPG+DHMA.",Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20220040/),[nM] / [l],0.57,202503,DB00190,Carbidopa
,32482490,Tmax,Median Tmax values with CVT-301 and oral CD/LD were 15 and 120 min (P < 0.001).,Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),min,15,205209,DB00190,Carbidopa
,32482490,Tmax,Median Tmax values with CVT-301 and oral CD/LD were 15 and 120 min (P < 0.001).,Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),min,120,205210,DB00190,Carbidopa
,32482490,Cmax,Cmax with CVT-301 was lower than with oral CD/LD (590.3 vs 844.3 ng/mL).,Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],590.3,205211,DB00190,Carbidopa
,32482490,Cmax,Cmax with CVT-301 was lower than with oral CD/LD (590.3 vs 844.3 ng/mL).,Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],844.3,205212,DB00190,Carbidopa
,32482490,C10min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],522.9,205213,DB00190,Carbidopa
,32482490,C10min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],531.5,205214,DB00190,Carbidopa
,32482490,C10min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],247.3,205215,DB00190,Carbidopa
,32482490,C30min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],531.5,205216,DB00190,Carbidopa
,32482490,C30min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],300.9,205217,DB00190,Carbidopa
,1773422,area under the curve [AUC],On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],2.10,215026,DB00190,Carbidopa
,1773422,area under the curve [AUC],On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],4.96,215027,DB00190,Carbidopa
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],4.05,215028,DB00190,Carbidopa
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],1.94,215029,DB00190,Carbidopa
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],3.91,215030,DB00190,Carbidopa
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],3.81,215031,DB00190,Carbidopa
,1490503,bioavailability,Almost equivalent bioavailability (85-90%) of levodopa was demonstrated for the controlled-release formulations relative to that of conventional Madopar capsules.,Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490503/),%,85-90,222528,DB00190,Carbidopa
,10829343,minimum detectable concentration,"Using this method, the minimum detectable concentration was estimated to be 5 and 8 ng ml-1 for L-dopa and C-dopa, respectively.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),[ng] / [ml],5,224309,DB00190,Carbidopa
,10829343,minimum detectable concentration,"Using this method, the minimum detectable concentration was estimated to be 5 and 8 ng ml-1 for L-dopa and C-dopa, respectively.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),[ng] / [ml],8,224310,DB00190,Carbidopa
,10829343,Recovery,"Recovery studies ranged from 93.83 to 89.76%, with a relative standard deviation of less than 7%.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),%,93.83 to 89.76,224311,DB00190,Carbidopa
less,10829343,half-lives,"The data also indicated a very low accumulation of both levodopa and carbidopa following repeated administration of the drugs, which was consistent with their relatively short half-lives (less than 2 h).",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),h,2,224312,DB00190,Carbidopa
,10829343,half-life,"In contrast, the half-life for the metabolite 3-orthomethyl dopa (3-OMD) is in the order of 13 h.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),h,13,224313,DB00190,Carbidopa
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],172.0,224639,DB00190,Carbidopa
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],258.3,224640,DB00190,Carbidopa
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],328.47,224641,DB00190,Carbidopa
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],387.3,224642,DB00190,Carbidopa
,18308795,oral clearance,5-HTP kinetics were adequately described using a one-compartment model with first-order absorption and a lag time (mean oral clearance 28 L/h interindividual coefficient of variation 31%).,Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[l] / [h],28,224643,DB00190,Carbidopa
,2685649,bioavailability,"Results indicate a levodopa bioavailability of 71% for Sinemet CR, in contrast to a bioavailability of 99% for Sinemet for these subjects.",Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685649/),%,71,225396,DB00190,Carbidopa
,2685649,bioavailability,"Results indicate a levodopa bioavailability of 71% for Sinemet CR, in contrast to a bioavailability of 99% for Sinemet for these subjects.",Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685649/),%,99,225397,DB00190,Carbidopa
,2685649,bioavailability,The carbidopa bioavailability of Sinemet CR was 58% relative to that of Sinemet.,Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685649/),%,58,225398,DB00190,Carbidopa
,19804823,absolute bioavailabilities,"The absolute bioavailabilities of oral and nasal preparations containing C-dopa were 17.7 and 45.4%, respectively.",Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19804823/),%,17.7,227456,DB00190,Carbidopa
,19804823,absolute bioavailabilities,"The absolute bioavailabilities of oral and nasal preparations containing C-dopa were 17.7 and 45.4%, respectively.",Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19804823/),%,45.4,227457,DB00190,Carbidopa
less,19804823,half-life,"Although the half-life after nasal administration was relatively short (less than 30 min) in both blood and brain regardless of C-dopa addition, the systemic exposure was promising due to rapid absorption.",Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19804823/),min,30,227458,DB00190,Carbidopa
,14718682,bioavailability,"In switching patients who are receiving levodopa/carbidopa controlled-release (CR), it should be noted that the bioavailability of levodopa from levodopa/carbidopa CR is approximately 70-75% that of levodopa/carbidopa IR products, including Stalevo.",Levodopa/carbidopa/entacapone (Stalevo). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14718682/),%,70-75,236483,DB00190,Carbidopa
,8314919,k0,"Population means for k0 (0.011 +/- 0.002 min-1) and k-1 (0.010 +/- 0.003 min-1) were used to generate ""simulated"" plasma curves.","Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314919/),1/[min],0.011,236798,DB00190,Carbidopa
,8314919,k-1,"Population means for k0 (0.011 +/- 0.002 min-1) and k-1 (0.010 +/- 0.003 min-1) were used to generate ""simulated"" plasma curves.","Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314919/),1/[min],0.010,236799,DB00190,Carbidopa
,24363125,absolute bioavailabilities,"The absolute bioavailabilities of nasal preparations with and without Carbopol were 82.4 and 66.7 %, respectively, which were much higher than that of oral delivery (16.2 %).",Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363125/),%,82.4,244438,DB00190,Carbidopa
,24363125,absolute bioavailabilities,"The absolute bioavailabilities of nasal preparations with and without Carbopol were 82.4 and 66.7 %, respectively, which were much higher than that of oral delivery (16.2 %).",Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363125/),%,66.7,244439,DB00190,Carbidopa
,24363125,absolute bioavailabilities,"The absolute bioavailabilities of nasal preparations with and without Carbopol were 82.4 and 66.7 %, respectively, which were much higher than that of oral delivery (16.2 %).",Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363125/),%,16.2,244440,DB00190,Carbidopa
,2775615,plasma clearance,2. The plasma clearance of levodopa following intravenous administration of 50 mg was 14.2 +/- 2.8 (s.d.) ml min-1 kg-1 in the elderly compared with 23.4 +/- 4.1 ml min-1 kg-1 in the young (P less than 0.01) which resulted in a 49% greater area under the plasma concentration-time curve (AUC) in the older subjects (P less than 0.01).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ml] / [kg·min],14.2,249584,DB00190,Carbidopa
,2775615,plasma clearance,2. The plasma clearance of levodopa following intravenous administration of 50 mg was 14.2 +/- 2.8 (s.d.) ml min-1 kg-1 in the elderly compared with 23.4 +/- 4.1 ml min-1 kg-1 in the young (P less than 0.01) which resulted in a 49% greater area under the plasma concentration-time curve (AUC) in the older subjects (P less than 0.01).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ml] / [kg·min],23.4,249585,DB00190,Carbidopa
,2775615,volume of distribution (Vss),The volume of distribution (Vss) was lower in the elderly (1.01 +/- 0.29 l kg-1) than in the young (1.65 +/- 0.39 l kg-1) (P less than 0.002).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[l] / [kg],1.01,249586,DB00190,Carbidopa
,2775615,volume of distribution (Vss),The volume of distribution (Vss) was lower in the elderly (1.01 +/- 0.29 l kg-1) than in the young (1.65 +/- 0.39 l kg-1) (P less than 0.002).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[l] / [kg],1.65,249587,DB00190,Carbidopa
,2775615,AUC,3. Following oral administration of 250 mg of levodopa the AUC was 2512 +/- 588 ng ml-1h in the elderly compared with 1056 +/- 282 ng ml-1h in the young (P less than 0.002).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ng] / [ml],2512,249588,DB00190,Carbidopa
,2775615,AUC,3. Following oral administration of 250 mg of levodopa the AUC was 2512 +/- 588 ng ml-1h in the elderly compared with 1056 +/- 282 ng ml-1h in the young (P less than 0.002).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ng] / [ml],1056,249589,DB00190,Carbidopa
,2775615,bioavailability,"The bioavailability of levodopa was significantly greater in the elderly (0.63 +/- 0.12 compared with 0.41 +/- 0.16, P less than 0.01).",The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),,0.63,249590,DB00190,Carbidopa
,2775615,bioavailability,"The bioavailability of levodopa was significantly greater in the elderly (0.63 +/- 0.12 compared with 0.41 +/- 0.16, P less than 0.01).",The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),,0.41,249591,DB00190,Carbidopa
,2775615,plasma clearance,"4. In the presence of carbidopa, the plasma clearance of intravenous levodopa (50 mg) was reduced in both age groups but remained lower in the elderly (5.8 +/- 0.9 ml min-1 kg-1 compared with 9.3 +/- 1.0 ml min-1 kg-1; P less than 0.01).",The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ml] / [kg·min],5.8,249592,DB00190,Carbidopa
,2775615,plasma clearance,"4. In the presence of carbidopa, the plasma clearance of intravenous levodopa (50 mg) was reduced in both age groups but remained lower in the elderly (5.8 +/- 0.9 ml min-1 kg-1 compared with 9.3 +/- 1.0 ml min-1 kg-1; P less than 0.01).",The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ml] / [kg·min],9.3,249593,DB00190,Carbidopa
,25112783,Cmax,"Levodopa Cmax was very similar in the initial situation (603.2 ng/ml) and after placebo administration (612.0 ng/ml), being slightly lower (547.8 ng/ml) when Plantago ovata husk was given.",A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25112783/),[ng] / [ml],603.2,249714,DB00190,Carbidopa
,25112783,Cmax,"Levodopa Cmax was very similar in the initial situation (603.2 ng/ml) and after placebo administration (612.0 ng/ml), being slightly lower (547.8 ng/ml) when Plantago ovata husk was given.",A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25112783/),[ng] / [ml],612.0,249715,DB00190,Carbidopa
,25112783,Cmax,"Levodopa Cmax was very similar in the initial situation (603.2 ng/ml) and after placebo administration (612.0 ng/ml), being slightly lower (547.8 ng/ml) when Plantago ovata husk was given.",A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25112783/),[ng] / [ml],547.8,249716,DB00190,Carbidopa
,25112783,AUC,"AUC was very similar in the three groups: initial situation.- 62.87 μg.min/ml, fiber treatment.- 64.47 μg.min/ml and placebo treatment.- 65.10 μg.min/ml.",A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25112783/),[min·μg] / [ml],62.87,249717,DB00190,Carbidopa
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],0.35,251269,DB00190,Carbidopa
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],0.82,251270,DB00190,Carbidopa
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],2.14,251271,DB00190,Carbidopa
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],3.27,251272,DB00190,Carbidopa
,11847938,time to Cmax,"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),h,4,251273,DB00190,Carbidopa
,2720699,Half-times,"Half-times for the equilibration between plasma and the effect compartment were 0.39 h for tapping, 0.36 h for walking, and 0.34 h for the global score.",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),h,0.39,254017,DB00190,Carbidopa
,2720699,Half-times,"Half-times for the equilibration between plasma and the effect compartment were 0.39 h for tapping, 0.36 h for walking, and 0.34 h for the global score.",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),h,0.36,254018,DB00190,Carbidopa
,2720699,Half-times,"Half-times for the equilibration between plasma and the effect compartment were 0.39 h for tapping, 0.36 h for walking, and 0.34 h for the global score.",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),h,0.34,254019,DB00190,Carbidopa
,2720699,Emax,"Pharmacodynamic data were fit best with an Emax model with baseline effect for tapping (Emax = 53.2 taps/60 s, EC50 = 0.58 microgram/ml) and global score (Emax set at 5.0 by limits of scale, EC50 = 2.53 micrograms/ml).",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),[taps] / [60·s],53.2,254020,DB00190,Carbidopa
,2720699,EC50,"Pharmacodynamic data were fit best with an Emax model with baseline effect for tapping (Emax = 53.2 taps/60 s, EC50 = 0.58 microgram/ml) and global score (Emax set at 5.0 by limits of scale, EC50 = 2.53 micrograms/ml).",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),[μg] / [ml],0.58,254021,DB00190,Carbidopa
,2720699,Emax,"Pharmacodynamic data were fit best with an Emax model with baseline effect for tapping (Emax = 53.2 taps/60 s, EC50 = 0.58 microgram/ml) and global score (Emax set at 5.0 by limits of scale, EC50 = 2.53 micrograms/ml).",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),,5.0,254022,DB00190,Carbidopa
,2720699,EC50,"Pharmacodynamic data were fit best with an Emax model with baseline effect for tapping (Emax = 53.2 taps/60 s, EC50 = 0.58 microgram/ml) and global score (Emax set at 5.0 by limits of scale, EC50 = 2.53 micrograms/ml).",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),[μg] / [ml],2.53,254023,DB00190,Carbidopa
,7575677,apparent rate constant,"In arterial plasma, FDOPA was O-methylated with an apparent rate constant (0.031 min-1) 3-fold that of [3H]DOPA in the same rats.","Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575677/),1/[min],0.031,263766,DB00190,Carbidopa
,7575677,rate constant,The O-methylated metabolite of FDOPA (OMe-FDOPA) was eliminated from plasma at a rate constant (0.018 min-1) 3-fold that of OMe-[3H]DOPA.,"Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575677/),1/[min],0.018,263767,DB00190,Carbidopa
,7575677,blood-brain clearance,The mean unidirectional blood-brain clearance of FDOPA (4.5 mL.hg-1.min-1) in six brain regions was 60% higher than that of [3H]DOPA.,"Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575677/),[ml] / [hg·min],4.5,263768,DB00190,Carbidopa
,18303486,ON time,"After the levodopa test doses, ON time significantly increased 29 minutes with 75 mg nebicapone, 45 minutes with 150 mg nebicapone, and 16 minutes with 200 mg entacapone.","Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303486/),min,29,266411,DB00190,Carbidopa
,18303486,ON time,"After the levodopa test doses, ON time significantly increased 29 minutes with 75 mg nebicapone, 45 minutes with 150 mg nebicapone, and 16 minutes with 200 mg entacapone.","Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303486/),min,45,266412,DB00190,Carbidopa
,18303486,ON time,"After the levodopa test doses, ON time significantly increased 29 minutes with 75 mg nebicapone, 45 minutes with 150 mg nebicapone, and 16 minutes with 200 mg entacapone.","Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303486/),min,16,266413,DB00190,Carbidopa
,8112370,area under the plasma concentration curve (AUC),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],3620,266437,DB00190,Carbidopa
,8112370,area under the plasma concentration curve (AUC),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],52,266438,DB00190,Carbidopa
,8112370,elimination half-life (t1/2el),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h,1.5,266439,DB00190,Carbidopa
,8112370,elimination half-life (t1/2el),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h,2.0,266440,DB00190,Carbidopa
,8112370,AUC,"The mean AUC of 3,4-dihydroxyphenylacetic acid (DOPAC), the monoamine oxidase-dependent metabolite of levodopa, was significantly increased from 122 to 343 h.micrograms.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h·μg,122,266441,DB00190,Carbidopa
,8112370,AUC,"The mean AUC of 3,4-dihydroxyphenylacetic acid (DOPAC), the monoamine oxidase-dependent metabolite of levodopa, was significantly increased from 122 to 343 h.micrograms.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h·μg,343,266442,DB00190,Carbidopa
,8112370,AUC,"A small decrease in the AUC of homovanillic acid (HVA), the COMT dependent metabolite of levodopa, was observed (from 455 to 303 h.ng.ml-1).","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],455,266443,DB00190,Carbidopa
,8112370,AUC,"A small decrease in the AUC of homovanillic acid (HVA), the COMT dependent metabolite of levodopa, was observed (from 455 to 303 h.ng.ml-1).","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],303,266444,DB00190,Carbidopa
,27163503,Maximum,Maximum S-COMT inhibition (Emax ) ranged from 67.8% (25 mg OPC) to 100% (100 mg OPC).,"Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163503/),%,67.8,270904,DB00190,Carbidopa
,27163503,Maximum,Maximum S-COMT inhibition (Emax ) ranged from 67.8% (25 mg OPC) to 100% (100 mg OPC).,"Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163503/),%,100,270905,DB00190,Carbidopa
